

**Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab)**  
**Recombinant Antibody**  
**Catalog # APR10262**

**Specification**

---

**Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P55899</a>
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	145.2 KDa

**Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) - Additional Information**

**Target/Specificity**  
FcRn (FCGRT & B2M)

**Endotoxin**  
< 0.001EU/ µg, determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) - Protein Information**

**Name** FCGRT

**Synonyms** FCRN

**Function**  
Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk (PubMed: [10933786](http://www.uniprot.org/citations/10933786), PubMed: [7964511](http://www.uniprot.org/citations/7964511)). IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium

and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation (PubMed:<a href="http://www.uniprot.org/citations/10998088" target="\_blank">10998088</a>). In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB (PubMed:<a href="http://www.uniprot.org/citations/24469444" target="\_blank">24469444</a>, PubMed:<a href="http://www.uniprot.org/citations/28330995" target="\_blank">28330995</a>).

#### Cellular Location

Cell membrane {ECO:0000250|UniProtKB:P13599}; Single-pass type I membrane protein.  
Endosome membrane

#### Tissue Location


Expressed in full-term placenta, heart, lung, liver, muscle, kidney, pancreas, and both fetal and adult small intestine.

### Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) - Images



Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab) is more than 97.55% ,determined by SEC-HPLC.



Immobilized FcRn(FCGRT) His+FcRn(B2M) at 2 µg/mL can bind Anti-FcRn (FCGRT & B2M) Reference Antibody (rozanolixizumab)  $EC_{50}=0.0103$  µg/mL